The abstract is read at the publisher; the summary is JClub's.
In symptomatic memory clinic, primary care, and research cohorts, plasma Lumipulse p-tau217 and p-tau217/Aβ42 identify Aβ-PET visual read pathology with AUC 0.90–0.96.
- Why it matters: Accessible plasma tests are needed to match regulatory CSF biomarker performance for detecting Alzheimer’s disease pathology without relying on lumbar puncture.
- What they did: They compared regulatory-authorized plasma p-tau217 and p-tau217/Aβ42 against regulatory-authorized CSF Aβ42/Aβ40 and p-tau181/Aβ42 using Aβ-PET visual read across cohorts (n=129, 220, 165).
- The result: With one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ42 (83–92%) had comparable accuracy to CSF (88–90%) across cohorts (all P≥0.05), and with two cutoffs plasma remained comparable in clinical cohorts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.